Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 66Recurrence 20Neoplasms, Plasma Cell 8Primary Myelofibrosis 3Polycythemia Vera 3Myeloproliferative Disorders 3Renal Insufficiency 2Plasmacytoma 2Lymphoma, Non-Hodgkin 2Immunoglobulin Light-chain Amyloidosis 2Central Nervous System Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Neurofibromatosis 1 1Neoplasms 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Intraocular Lymphoma 1Hodgkin Disease 1Glioma 1

Interventions

Dexamethasone 5Magnetic Resonance Spectroscopy 4Cyclophosphamide 4Blood Specimen Collection 4Surveys and Questionnaires 3Prednisone 3Melphalan 3Lenalidomide 3Biopsy, Fine-Needle 3fluciclovine F-18 2carfilzomib 2Positron-Emission Tomography 2Mammography 2Injections 2Immunohistochemistry 2Gemcitabine 2Cytarabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2weifuchun 1vistusertib 1venetoclax 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1ricolinostat 1pomalidomide 1phosphoribosylformylglycinamidine synthetase 1pembrolizumab 1ofatumumab 1obinutuzumab 1lortalamine 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Disease × pomalidomide × Clear all
NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡